WIXOM, Mich., Oct. 6, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported today that it has added Jur Strobos M.D. to its Scientific Advisory Board (SAB). Rockwell’s SAB currently advises the Company on clinical development for its proprietary iron-maintenance drug SFP, currently in FDA clinical development.
